Last checked at 31 Aug 2016 11:37
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Scancell Holdings Share News (SCLP)
SCLP Share
Price
SCLP Share
News
SCLP Share
Chat15
SCLP Share
Trades4
SCLP
Live RNS1
SCLP Share
Charts
SCLP Level 2
Console
SCLP Live
Share Price
SCLP Broker
Ratings
SCLP Directors
Deals
SCLP Financial
Diary
SCLP
Fundamentals
SCLP Short
Positions
SCLP
Media
Scancell Holdings Information
Share Price Information for Scancell Holdings (SCLP)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
10.00
Bid:
9.50
Ask:
10.50
Change:
0.25 (2.56%)
Spread:
1.00 (10.526%)
Open:
9.75
High:
10.00
Low:
9.75
Prev. Close:
9.75
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Scancell reports encouraging results of melanoma treatment
Mon, 02nd Jun 2014 11:08
Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electroporation device. Five of 11 patients in the first part of the trial receiving 2mg, 4mg or 8mg doses have shown evidence of a clinical response. Part 1 patients receiving 2mg and 4mg doses of SCIB1 had one-year and two-year survival rates of 100% and 67%, respectively All 14 patients in the second part of the study with resected tumours are still alive 16-24 months after study entry."As positive and consistent data continues to emerge from this study, our confidence grows that SCIB1 will play an important role in the management of melanoma," said Chief Executive Lindy Durrant. "While recognising the limitations of this open label trial, the results nonetheless detail a high rate of immune responders and a strong immune response with a drug that is well-tolerated and safe."Shares rose 4.41% to 35.50p at 11:24 on Monday.RD
More News
20 Jul 2016 12:35
Scancell granted product licence extension from Ichor Medical Systems
(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,
Read more17 Jun 2016 12:24
Scancell suspends dosing with current supplies of SCIB1 for melanoma
(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the
Read more17 Jun 2016 08:10
UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial
(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te
Read more17 Jun 2016 07:46
BUZZ-Scancell: drug problem spurs worst day in 3 yrs
** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s
Read more17 Jun 2016 06:51
Drug problem forces Scancell to suspend cancer trial dosing
LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer
Read more